We would love to hear your thoughts about our site and services, please take our survey here.
So why did you not buy when the price was £3,85
Here is the news released today
TIDMPRM
RNS Number : 2669O
Proteome Sciences PLC
02 October 2023
2 October 2023
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Launch of Commercial Single Cell Proteomics Services
Proteome Sciences plc is pleased to announce the launch of SysQuant(R)
SCP, the commercial service for single cell proteomics using the
power of its TMTpro(TM) isobaric labelling reagents. Where more
traditional approaches can measure a few 10s of proteins on each
cell using antibody labelling, SysQuant(R) SCP can identify more
than 1,000 proteins in each study of 576 single cells and provides
novel insights into individual cell biology and heterogeneity.
Proteome Sciences is one of the first commercial providers of such
studies which are expected to significantly improve the performance
of drug development across multiple diseases including cancer,
neurodegeneration, respiratory and cardiac health, and metabolic
disorders. Whilst in its infancy, the field of single cell proteomics
is expected to grow rapidly as drug developers look to integrate
single cell genomic data with knowledge of protein changes. At
the same time, the complexity of the process along with the need
to purchase and maintain costly equipment represents a significant
barrier to entry.
The SysQuant(R) SCP pipeline generates and analyses quantitative
mass spectrometry data to reveal subtle changes not only in individual
cells but also within sub-populations of that same main cell type.
This data will greatly improve understanding of the biological
drivers of heterogeneity and evolution in the contexts of disease
and response to therapy, which will offer new therapeutic and diagnostic
targets for personalized medicine.
Commenting on the launch of SysQuant(R) SCP, Dr. Ian Pike Chief
Scientific Officer stated:
"This is an important step for Proteome Sciences as we have adapted
cutting-edge techniques developed in academia to make them available
to the pharmaceutical and biotechnology industries through SysQuant(R)
SCP. We have built a robust platform that will provide customers
with transformational data enabling a deeper understanding of disease
biology and how drugs are interacting with their targets. SysQuant(R)
SCP studies are highly complementary to our established workflows
performed on larger samples and open up a new customer base needing
access to this valuable novel single cell information."
Dr. Mariola Soehngen, Chief Executive Officer commented:
"We are pleased to be one of the first CROs providing single cell
proteomics to our customers. The launch of SysQuant(R) SCP is part
of our growth strategy along with the opening of a US facility
in San Diego. We believe that broadening our range of services
and incr
Why is the rns not showing this morning
Yes a dip in earnings don't deserve a 30% drop in share price
I was expecting better, not expecting a dip in earnings
It's nice to see a bit of blue for a change
Contrarian123 The market seems to disagree with you and i would say anyone sorting at this price are taking a big risk.
Day after day so many late delayed buys and with a bit of a tree shake this morning i still think we have a long way to go
Here comes the big delayed buys again
A lot of late buys coming in
And the 6 month chart looks very good
Thats some turn around today
HVO Professional News
IN THE KNOW: hVIVO involvement in drug approval should boost interest
Fri, 02nd Jun 2023 21:42Alliance News
(Alliance News) - hVIVO's involvement in the approval of pharmaceutical giant Pfizer's new vaccine Abrysvo should support interest in its services, according to Liberum.
On Wednesday, the US Food & Drug Administration approved Pfizer's respiratory syncytial virus vaccine for older adults, Abrysvo, and human challenge study data produced by hVIVO was instrumental in its approval.
It also played an essential role in earning the vaccine FDA breakthrough therapy designation that helped accelerate clinical development and approval by around 12 months, and meant that Pfizer's drug has been approved within a month of GSK's rival vaccine.
Pfizer and GSK's RSV vaccines are set to go head-to-head, with both set to launch in the third quarter, ahead of the next RSV season.
Liberum thinks the approval serves as a milestone for the human challenge study field, and said "we should see new RSV vaccine shots enter development and catalyse wider interest in other infectious diseases."
The broker explained that "hVIVO is the only commercial provider of human challenge studies in RSV and this milestone supports interest in hVIVO's services."
Liberum believes hVIVO is its 2023 small- and mid-cap healthcare best idea and keeps a 'buy' rating and unchanged target price of 26.30 pence.
Shares in hVIVO closed 3.2% lower at 15.25 pence in London on Friday.
By Jeremy Cutler, Alliance News reporter
Comments and questions to newsroom@alliancenews.com